Cover Image
市場調查報告書

Frontier Pharma:乳癌 - First-in-Class的革新認識和商業化

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

出版商 GBI Research 商品編碼 354830
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:乳癌 - First-in-Class的革新認識和商業化 Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes
出版日期: 2016年02月16日 內容資訊: 英文 79 Pages
簡介

乳癌治療藥的開發平台,在製藥產業中最大,在全階段中有1,050項產品正在開發。

本報告提供乳癌治療藥市場相關調查分析,革新案例,臨床、商業性情形,開發中產品的評估,計劃評估,最近的交易等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 革新案例

  • 生技藥品的機會擴大
  • 分子標的多樣化
  • 創新的First-in-Class產品 (劃時代的醫藥品) 的開發現在也富有魅力
  • 法規、償付政策,對First-in-Class產品的革新有利
  • 持續性的革新
  • 報告指南

第4章 臨床、商業性情形

  • 疾病概要
  • 流行病學
  • 疾病的症狀
  • 病因
  • 病理生理學
  • 診斷
  • 預後和分期
  • 關於治療
  • 手術、放射線治療
  • 上市產品概要
  • 治療流程
  • 目前未滿足需求

第5章 開發中產品革新的評估

  • 乳癌治療藥開發平台:各階段、分子類型、分子標的
  • First-in-Class開發平台計劃

第6章 信號 (信號傳達) 網路,疾病的因果關係,革新的調整

  • 信號傳達網路的複雜
  • 信號傳達途徑,成為疾病原因的變異,First-in-Class分子標的整合
  • First-in-Class標的矩陣的評估

第7章 First-in-Class標的評估

第8章 交易與策略性整合

  • 產業整體First-in-Class交易
  • 乳癌治療藥交易形勢
  • 許可證交易
  • 共同開發交易
  • 不參與許可證/共同開發交易的First-in-Class計劃

第9章 附錄

圖表

目錄
Product Code: GBIHC402MR

Executive Summary

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional – GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

Scope

  • The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
  • A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
  • The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
  • Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Reasons to buy

  • Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
  • Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
  • Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
  • Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Exceptionally Large and Innovative Pipeline
  • 2.2. Alignment of First-in-Class Molecular Target with Disease Causation
  • 2.3. Highly Active Deals Landscape with Numerous Investment Opportunities

3. The Case for Innovation in the Breast Cancer Market

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Developments Remain Attractive
  • 3.4. Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications
  • 3.5. Sustained Innovation
  • 3.6. Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
  • 4.2. Epidemiology
  • 4.3. Disease Symptoms
  • 4.4. Etiology
    • 4.4.1. Age and Gender
    • 4.4.2. Genetic Makeup
    • 4.4.3. Environmental
  • 4.5. Pathophysiology
    • 4.5.1. Tumor Initiation and Aberrant Cell Proliferation and Survival
    • 4.5.2. Tumor Metabolic Shift
    • 4.5.3. Tumor Progression, Micro-environment Alteration and Angiogenesis
    • 4.5.4. Cancer Stem Cells
  • 4.6. Diagnosis
  • 4.7. Prognosis and Disease Staging
    • 4.7.1. Classification
  • 4.8. Introduction to Breast Cancer Treatments
  • 4.9. Surgery and Radiation Therapy
  • 4.10. Overview of Marketed Products for Breast Cancer
    • 4.10.1. Chemotherapy
    • 4.10.2. Hormonal Therapies
    • 4.10.3. Targeted Therapies
  • 4.11. Treatment Algorithm
  • 4.12. Current Unmet Need in Breast Cancer Market

5. Assessment of Pipeline Product Innovation

  • 5.1. Breast Cancer Pipeline by Phase, Molecule Type and Molecular Target
  • 5.2. First-in-Class Pipeline Programs

6. Signaling Network, Disease Causation and Innovation Alignment

  • 6.1. The Complexity of Signaling Networks in Oncology
  • 6.2. Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Target Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs which Target FGFR 3 and 4
  • 7.2. Pipeline Programs which Target HER3
  • 7.3. Pipeline Programs which Target PDK1
  • 7.4. Pipeline Programs which Target Akt 1, 2 and 3
  • 7.5. Pipeline Programs which Target PI3K-alpha
  • 7.6. Conclusion

8. Deals and Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Breast Cancer Deals Landscape
  • 8.3. Licensing Deals
    • 8.3.1. Molecule Type
    • 8.3.2. Molecular Target
  • 8.4. Co-development Deals
    • 8.4.1. Molecule Type
    • 8.4.2. Molecular Target
  • 8.5. First-In-Class Molecules not Involved in Licensing or Co-development Deals

9. Appendix

  • 9.1. Abbreviations
  • 9.2. References
  • 9.3. Contact Us
  • 9.4. Disclaimer

List of Tables

  • Table 1: Tumor, regional lymph Node and Metastasis Staging, 2010-2013
  • Table 2: US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013
  • Table 3: Breast Cancer Histopathological and Molecular Classification
  • Table 4: Key Features and Pipeline Activity of FGFR3
  • Table 5: Key Features and Pipeline Activity of FGFR4
  • Table 6: Pipeline Programs Targeting FGFR4
  • Table 7: Key Features and Pipeline Activity of HER3
  • Table 8: Key Features and Pipeline Activity of PDPK1
  • Table 9: Key Features and Pipeline Activity of Akt1
  • Table 10: Key Features and Pipeline Activity of Akt2
  • Table 11: Key Features and Pipeline Activity of Akt3
  • Table 12: Key Features and Pipeline Activity of PI3K-alpha

List of Figures

  • Figure 1: Marketed Product Overview
  • Figure 2: Treatment Algorithm for Cancer Diagnosed at Stages I to III
  • Figure 3: Treatment Algorithm for Cancer Diagnosed at Stage IV
  • Figure 4: Developmental Pipeline Overview
  • Figure 5: Developmental Pipeline Molecular Target Categories
  • Figure 6: Molecular Target Category Comparison, Pipeline and Marketed Products
  • Figure 7: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets
  • Figure 8: First-in-Class Products in the Breast Cancer Pipeline, Part 1
  • Figure 9: First-in-Class Products in the Breast Cancer Pipeline, Part 2
  • Figure 10: First-in-Class Products in the Breast Cancer Pipeline, Part 3
  • Figure 11: First-in-Class Products in the Breast Cancer Pipeline, Part 4
  • Figure 12: First-in-Class Molecular Target Analysis Matrix
  • Figure 13: First-in-Class Molecular Target Analysis Matrix
  • Figure 14: First-in-Class Molecular Target Analysis Matrix
  • Figure 15: Pipeline Programs Targeting FGFR3
  • Figure 16: Pipeline Programs Targeting HER3
  • Figure 17: Pipeline Programs Targeting PDK1
  • Figure 18: Pipeline Programs Targeting Akt1
  • Figure 19: Pipeline Programs Targeting Akt2
  • Figure 20: Pipeline Programs Targeting Akt3
  • Figure 21: Pipeline Programs Targeting PI3K
  • Figure 22: Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 23: Industry Licensing Deal Values by Stage of Development ($m), 2006-2014
  • Figure 24: Global, Licensing Deals by Region and Value, 2006-2014
  • Figure 25: Global, Licensing Deals by Stage and Value, 2006-2014
  • Figure 26: Licensing Deals by Molecule Type, 2006-2014
  • Figure 27: Licensing Deals by Molecular Target, 2006-2014
  • Figure 28: Licensing Deals, 2006-2014
  • Figure 29: Licensing Deals, 2006-2014
  • Figure 30: Co-Development Deals, 2006-2014
  • Figure 31: Co-Development Deals, 2006-2014
  • Figure 32: Co-Development Deals by Molecule Type, 2006-2014
  • Figure 33: Co-Development Deals by Molecular Target, 2006-2014
  • Figure 34: Co-Development Deals, 2006-2014
  • Figure 35: First-in-Class Programs with no Prior Deal Involvement, Part 1
  • Figure 36: First-in-Class Programs with no Prior Deal Involvement, Part 2
  • Figure 37: First-in-Class Programs with no Prior Deal Involvement, Part 3
Back to Top